Two Israeli startups were among the three finalists in the Cardiovascular Research Foundation’s Shark Tank Innovation competition held at the 2017 TCT Conference in Denver, Colorado. Enopace won, with its left ventricular neurostimulator (see here). Paragate’s fluid removal device came … Continue reading →

Israel’s Enopace (see Mar 2013 newsletter) has seen the first operation to implant its new catheter-based neuro-stimulator to treat patients with congestive heart failure. The procedure was performed by Professor Davor Milicic, head of Cardiology at Zagreb Medical University. http://www.prnewswire.com/news-releases/worlds-first-endovascular-neuromodulation-device-implanted-in-man-for-the-treatment-of-congestive-heart-failure-540696751.html

Israel’s Enopace Biomedical is developing an endovascular micro-stimulator, which reduces the strain on the heart by expanding the arteries to accept incoming blood. It is implanted by catheter in a 30-minute procedure while the patient is awake and is an … Continue reading →

Israel’s Enopace Biomedical is developing a non-invasive implant that prevents heart failure by easing the pressure in the left ventricle and improving blood flow to the heart. It could be the biggest breakthrough treatment for congestive heart failure. http://www.globes.co.il/serveen/globes/docview.asp?did=1000690826&fid=1725